Renal benefits of GLP-1 receptor agonists: evidence from recent outcome trials
In this medfyle
Expert commentary by Prof. Tatjana Milenkovic
This Medfyle was published more than two years ago. More recent Medfyle on this topic may now be available.
Acknowledgements
This is a highlights summary of an oral session given at the Virtual EASD Annual Meeting 2021 and presented by:
Dr. Ofri Mosenzon
Hadassah Medical Centre, Hebrew University of Jerusalem
Jerusalem, Israel
The content is produced by Infomedica. The presenting authors of the original session had no part in the creation of this conference highlights summary.
In addition, an expert commentary on the topic has been provided by:
Prof. Tatjana Milenkovic
Professor of Internal medicine,
University St. Ciryl and Methodius, Endocrinologist at University Clinic of Endocrinology, Diabetes and Metabolic Disorders
Skopje, North Macedoni
About the Expert
Prof. Tatjana Milenkovic
Professor of Internal medicine,
University St. Ciryl and Methodius, Endocrinologist at University Clinic of Endocrinology, Diabetes and Metabolic Disorders
Skopje, North Macedonia
Tatjana Milenkovic is a Professor of internal medicine at the University “St Cyril and Methodius”, Medical Faculty in Skopje, Macedonia. She works at the Clinic of Endocrinology, Diabetes and Metabolic Diseases since 1985, where in 1995 she has established the Department of education of people with diabetes - and she has been Head of the department ever since. She is a member of the Executive Committee and President elect of Diabetes Education Study Group (DESG). She is the President of Macedonian Diabetes Association, since 2013, the President of the Macedonian Scientific Association of endocrinologists and diabetologists since 2014, member of IDF Europe board for biennium 2020/2021. She is a member of ESE educational committee 2021-2025.
Disclosures: Advisory board and lecturer - NovoNordisk, Boehringer, Sanofi.
References
1. Leiter LA, Carr MC, Stewart M, et al. Efficacy and safety of the once-weekly GLP-1 receptor agonist albiglutide versus sitagliptin in patients with type 2 diabetes and renal impairment: a randomized phase III study. Diabetes Care. 2014;37(10):2723-30.
2. Davies MJ, Bain SC, Atkin SL, et al. Efficacy and Safety of Liraglutide Versus Placebo as Add-on to Glucose-Lowering Therapy in Patients With Type 2 Diabetes and Moderate Renal Impairment (LIRA-RENAL): A Randomized Clinical Trial. Diabetes Care. 2016;39(2):222-30.
3. Tuttle KR, Lakshmanan MC, Rayner B, et al. Dulaglutide versus insulin glargine in patients with type 2 diabetes and moderate-to-severe chronic kidney disease (AWARD-7): a multicentre, open-label, randomised trial. Lancet Diabetes Endocrinol. 2018;6(8):605-617.
4. Mosenzon O, Blicher TM, Rosenlund S, et al. Efficacy and safety of oral semaglutide in patients with type 2 diabetes and moderate renal impairment (PIONEER 5): a placebo-controlled, randomised, phase 3a trial. Lancet Diabetes Endocrinol. 2019;7(7):515-527.
5. Mann JFE, Fonseca V, Mosenzon O, et al. Effects of Liraglutide Versus Placebo on Cardiovascular Events in Patients With Type 2 Diabetes Mellitus and Chronic Kidney Disease. Circulation. 2018;138(25):2908-2918.
6. Kristensen SL, Rørth R, Jhund PS, et al. Cardiovascular, mortality, and kidney outcomes with GLP-1 receptor agonists in patients with type 2 diabetes: a systematic review and meta-analysis of cardiovascular outcome trials. Lancet Diabetes Endocrinol. 2019;7(10):776-785.
7. Sattar N, Lee MMY, Kristensen SL, et al. Cardiovascular, mortality, and kidney outcomes with GLP-1 receptor agonists in patients with type 2 diabetes: a systematic review and meta-analysis of randomised trials. Lancet Diabetes Endocrinol. 2021;9(10):653-662.
8. American Diabetes Association. 9. Pharmacologic Approaches to Glycemic Treatment: Standards of Medical Care in Diabetes-2021. Diabetes Care. 2021;44(Suppl 1):S111-S124.
9. Kidney Disease: Improving Global Outcomes (KDIGO) Diabetes Work Group. KDIGO 2020 Clinical Practice Guideline for Diabetes Management in Chronic Kidney Disease. Kidney Int. 2020;98(4S):S1-S115.
